Integra LifeSciences Q4 Adjusted Earnings, Revenue Increase; Q1, 2025 Outlook Issued

MT Newswires Live

Feb 25, 2025

Integra LifeSciences (IART) reported Q4 adjusted earnings Tuesday of $0.97 per diluted share, up from $0.89 a year earlier.

Analysts polled by FactSet expected $0.85.

Revenue for the quarter ended Dec. 31 was $442.6 million, up from $397.0 million a year earlier.

Analysts surveyed by FactSet expected $445.1 million.

For Q1, the biopharmaceutical company expects adjusted diluted EPS of $0.40 to $0.45 on revenue of $375 million to $385 million. Analysts polled by FactSet expect non-GAAP EPS of $0.56 on revenue of $411.7 million.

For 2025, the company expects adjusted diluted EPS of $2.41 to $2.51 on revenue of $1.65 billion to $1.72 billion. Analysts polled by FactSet expect non-GAAP EPS of $2.51 on revenue of $1.71 billion.

Shares of the company were down more than 2% in recent premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2514060851"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514060851\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514060851?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 19:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514060851","market":"fut","top_or_hot":-1,"title":"Integra LifeSciences Q4 Adjusted Earnings, Revenue Increase; Q1, 2025 Outlook Issued","media":"MT Newswires Live","content":"<html><body><p> Integra LifeSciences (IART) reported Q4 adjusted earnings Tuesday of $0.97 per diluted share, up from $0.89 a year earlier.</p><p>Analysts polled by FactSet expected $0.85.</p><p>Revenue for the quarter ended Dec. 31 was $442.6 million, up from $397.0 million a year earlier.</p><p>Analysts surveyed by FactSet expected $445.1 million.</p><p>For Q1, the biopharmaceutical company expects adjusted diluted EPS of $0.40 to $0.45 on revenue of $375 million to $385 million. Analysts polled by FactSet expect non-GAAP EPS of $0.56 on revenue of $411.7 million.</p><p>For 2025, the company expects adjusted diluted EPS of $2.41 to $2.51 on revenue of $1.65 billion to $1.72 billion. Analysts polled by FactSet expect non-GAAP EPS of $2.51 on revenue of $1.71 billion.</p><p>Shares of the company were down more than 2% in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Integra LifeSciences Q4 Adjusted Earnings, Revenue Increase; Q1, 2025 Outlook Issued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntegra LifeSciences Q4 Adjusted Earnings, Revenue Increase; Q1, 2025 Outlook Issued\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-25 19:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Integra LifeSciences (IART) reported Q4 adjusted earnings Tuesday of $0.97 per diluted share, up from $0.89 a year earlier.</p><p>Analysts polled by FactSet expected $0.85.</p><p>Revenue for the quarter ended Dec. 31 was $442.6 million, up from $397.0 million a year earlier.</p><p>Analysts surveyed by FactSet expected $445.1 million.</p><p>For Q1, the biopharmaceutical company expects adjusted diluted EPS of $0.40 to $0.45 on revenue of $375 million to $385 million. Analysts polled by FactSet expect non-GAAP EPS of $0.56 on revenue of $411.7 million.</p><p>For 2025, the company expects adjusted diluted EPS of $2.41 to $2.51 on revenue of $1.65 billion to $1.72 billion. Analysts polled by FactSet expect non-GAAP EPS of $2.51 on revenue of $1.71 billion.</p><p>Shares of the company were down more than 2% in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IART","symbol_name":"英特格拉生命科学","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2514060851","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514060851","pubTimestamp":1740483330,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Integra LifeSciences  reported Q4 adjusted earnings Tuesday of $0.97 per diluted share, up from $0.89 a year earlier.Analysts polled by FactSet expected $0.85.Revenue for the quarter ended Dec. 31 was $442.6 million, up from $397.0 million a year earlier.Analysts surveyed by FactSet expected $445.1 million.For Q1, the biopharmaceutical company expects adjusted diluted EPS of $0.40 to $0.45 on revenue of $375 million to $385 million. Analysts polled by FactSet expect non-GAAP EPS of $0.56 on revenue of $411.7 million.For 2025, the company expects adjusted diluted EPS of $2.41 to $2.51 on revenue of $1.65 billion to $1.72 billion. Analysts polled by FactSet expect non-GAAP EPS of $2.51 on revenue of $1.71 billion.Shares of the company were down more than 2% in recent premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IART":"英特格拉生命科学"},"translate_title":"Integra LifeSciences第四季度调整后盈利、收入增长；发布2025年第一季度展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IART":0.9},"content_text":"Integra LifeSciences (IART) reported Q4 adjusted earnings Tuesday of $0.97 per diluted share, up from $0.89 a year earlier.Analysts polled by FactSet expected $0.85.Revenue for the quarter ended Dec. 31 was $442.6 million, up from $397.0 million a year earlier.Analysts surveyed by FactSet expected $445.1 million.For Q1, the biopharmaceutical company expects adjusted diluted EPS of $0.40 to $0.45 on revenue of $375 million to $385 million. Analysts polled by FactSet expect non-GAAP EPS of $0.56 on revenue of $411.7 million.For 2025, the company expects adjusted diluted EPS of $2.41 to $2.51 on revenue of $1.65 billion to $1.72 billion. Analysts polled by FactSet expect non-GAAP EPS of $2.51 on revenue of $1.71 billion.Shares of the company were down more than 2% in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}